Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Minami, Toshiyuki ^a   Kijima, Takashi ^a   Kohmo, Satoshi ^a   Arase, Hisashi ^b,c   Otani, Yasushi ^a   Nagatomo, Izumi ^a   Takahashi, Ryo ^a   Miyake, Kotaro ^a   Higashiguchi, Masayoshi ^a   Morimura, Osamu ^a   Ihara, Shoichi ^a   Tsujino, Kazuyuki ^a   Hirata, Haruhiko ^a   Inoue, Koji ^a   Takeda, Yoshito ^a   Kida, Hiroshi ^a   Tachibana, Isao ^a   Kumanogoh, Atsushi ^a,b,c  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; TRASTUZUMAB; VASCULOTROPIN A;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MOUSE; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; LUNG NEOPLASMS; MALE; MICE; RECEPTOR, ERBB-2; SMALL CELL LUNG CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884255642     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02669     Document Type: Article

References (47)

1. Rodriguez, E. & Lilenbaum, R. C. Small cell lung cancer: past, present, and future. Curr Oncol Rep 12, 327-334 (2010).
2. Hanna, N. H. & Einhorn, L. H. Small-cell lung cancer: state of the art. Clin Lung Cancer 4, 87-94 (2002). (Pubitemid 35174865)
3. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346, 85-91 (2002). (Pubitemid 34438898)
4. Rossi, A., Martelli, O. & Di Maio, M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev 39, 498-506 (2013).
5. Johnson, B. E. et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9, 5880-5887 (2003). (Pubitemid 38018071)
6. Moore, A. M. et al. Gefitinib in patients with chemo-sensitive and chemorefractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52, 93-97 (2006). (Pubitemid 43340205)
7. Fischer, B., Marinov, M. & Arcaro, A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33, 391-406 (2007). (Pubitemid 46760526)
8. Ménard, S., Tagliabue, E., Campiglio, M. & Pupa, S. M. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182, 150-162 (2000). (Pubitemid 30022667)
9. Slamon,D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989). (Pubitemid 19147683)
10. Ross, J. S. & Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413-428 (1998). (Pubitemid 28524507)
11. Micke, P. et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92, 474-479 (2001). (Pubitemid 32319418)
12. Potti, A. et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36, 257-261 (2002). (Pubitemid 34497123)
13. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792 (2001). (Pubitemid 32222155)
14. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
15. Jones, K. L.&Buzdar, A. U. Evolving novel anti-HER2 strategies. Lancet Oncol 10, 1179-1187 (2009).
16. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6, 443-446 (2000). (Pubitemid 30208162)
17. Lagadec, P. F., Saraya, K. A. & Balkwill, F. R. Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int J Cancer 48, 311-317 (1991).
18. Savas, B., Kerr, P. E., Ustun, H., Cole, S. P. & Pross, H. F. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. Anticancer Res 18, 4355-4361 (1998). (Pubitemid 29043659)
19. Minami, T. et al. HER2 as Therapeutic Target for Overcoming ATP-binding Cassette Transporter-Mediated Chemoresistance in Small Cell Lung Cancer. Mol Cancer Ther 11, 830-841 (2012).
20. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25, 118-145 (2007). (Pubitemid 350003059)
21. Ross, J. S. et al. The HER-2 receptor and breast cancer: ten years of targeted anti- HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009).
22. Ganti, A. K. & Panwalkar, A. W. Targeted therapy for small cell lung cancer. Targ Oncol 2, 89-97 (2007).
23. Ruschoff, J. et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 25, 637-650 (2012).
24. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20, 719-726 (2002). (Pubitemid 34111379)
25. Baselga, J. et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23, 2162-2171 (2005). (Pubitemid 46218708)
26. Paik, S., Kim, C. & Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358, 1409-1411 (2008). (Pubitemid 351468442)
27. Helander, T. S. & Timonen, T. Adhesion in NK cell function. Curr Top Microbiol Immunol 230, 89-99 (1998). (Pubitemid 28183719)
28. Barber, D. F., Faure, M.&Long, E. O. LFA-1 contributes an early signal forNKcell cytotoxicity. J Immunol 173, 3653-3659 (2004). (Pubitemid 39280725)
29. Bryceson, Y. T., March, M. E., Barber, D. F., Ljunggren, H. G. & Long, E. O. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 202, 1001-1012 (2005). (Pubitemid 41396899)
30. Bryceson, Y. T., March, M. E., Ljunggren, H. G. & Long, E. O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214, 73-91 (2006). (Pubitemid 44707903)
31. Ready, N. E. et al. Cisplatin, irinotecan, and bevacizumab for untreated extensivestage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 29, 4436-4441 (2011).
32. Spigel, D. R. et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29, 2215-2222 (2011).
33. Burris, H. A., 3rd. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29, 398-405 (2011).
34. Teicher, B. A. & Chari, R. V. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17, 6389-6397 (2011).
35. Junttila, T. T., Li, G., Parsons, K., Phillips, G. L.&Sliwkowski, M. X. Trastuzumab- DM1(T-DM1) retains all themechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128, 347-356 (2011).
36. Mitsuhashi, Y., Inaba, M., Sugiyama, Y. & Kobayashi, T. In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 70, 2540-2546 (1992).
37. Hong, W. S. et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 41, 462-467 (1988).
38. Minato, K. et al. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26, 313-317 (1990). (Pubitemid 20271531)
39. Moritaka, T. et al. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18, 927-933 (1998). (Pubitemid 28239618)
40. Takigawa, N., Ohnoshi, T., Ueoka, H., Kiura, K. & Kimura, I. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46, 203-212 (1992).
41. Chikamori, M. et al. Establishment of a 7-ethyl-10-hydroxy- camptothecinresistant small cell lung cancer cell line. Anticancer Res 24, 3911-3916 (2004). (Pubitemid 40468685)
42. Drexler, H. G.&Matsuo, Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 14, 777-782 (2000). (Pubitemid 30235051)
43. Chen, X. et al. CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells. Proc Natl Acad Sci U S A 103, 10346-10351 (2006). (Pubitemid 44051169)
44. Robertson, M. J. et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24, 406-415 (1996). (Pubitemid 26098857)
45. Lammerts van Bueren, J. J. et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66, 7630-7638 (2006).
46. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58, 2825-2831 (1998). (Pubitemid 28311914)
47. Cascone, T. et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121, 1313-1328 (2011).